PDF
Full
Outline
To investigate the clinical efficacy of 3HRZE/6HRE regimen assisted by Bushen Huoxue Formula in the treatment of patients with intermediate and advanced renal tuberculosis, and to analyze the safety of this therapeutic strategy.
The clinical data of 122 patients with advanced renal tuberculosis who were treated in Shaanxi Provincial Tuberculosis Prevention and Treatment Hospital from March 2021 to June 2024 were retrospectively analyzed. According to different treatment regimens, they were divided into control group and observation group. 61 patients in the control group were treated with 3HRZE/6HRE regimen alone. 61 patients in the observation group were treated with Bushen Huoxue Formula combined with 3HRZE/6HRE regimen. The course of treatment was 9 months. The clinical efficacy, inflammatory response [interferon-gamma (IFN-γ), interleukin-6 (IL-6), blood sedimentation rate (ESR)], liver and kidney function [azelaic transaminase (AST), blood urea nitrogen (BUN), quantitative 24 h urinary protein (24 h UTP)], quality of life determination scale (QLICD-PT) scores, and the incidence rate of adverse reactions were observed in the two groups.
The total effective rate of the observation group was higher than that of the control group (P <0.05). After treatment, the levels of IFN-γ, IL-6, ESR, BUN, and 24 h UTP were lower than those before treatment in both groups (P <0.05), and the observation group was lower than the control group (P <0.05); and the levels of AST and the scores of each dimension of QLICD-PT were higher than those before treatment, and the observation group was higher than the control group (P <0.05). There was no statistically significant difference in the incidence of adverse reactions in the observation group compared with the control group (P > 0.05).
Bushen Huoxue Formula assisted 3HRZE/6HRE regimen in treating patients with intermediate and advanced renal tuberculosis can significantly improve the therapeutic efficacy and quality of survival, and improve the liver and kidney function, inhibit the expression of inflammation, and have a good safety.
PDF
5
1
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
